Praxis Precision climbs after FDA's 'breakthrough' tag for tremor drug

Praxis Precision Medicines

29/12/2025 14:48

Updates

** Shares of drug developer Praxis Precision Medicines PRAX.O rise 14.9% to $309.03

** PRAX says U.S. Food and Drug Administration has granted "breakthrough" tag for its experimental drug, ulixacaltamide, to treat patients with essential tremor

** The breakthrough therapy tag is meant to speed up development and review of drugs to treat serious conditions or those with unmet medical needs

** Essential tremor is a neurological movement disorder that causes involuntary, rhythmic shaking in the hands, arms, head or voice

** Including session's moves, stock has more than tripled YTD

 (Reporting by Siddhi Mahatole)

 ((siddhi.mahatole@thomsonreuters.com))